What Sinopharm does

Sinopharm Group Industrial Co., Ltd. (国药集团工业有限公司) is a Chinese state-designated pharmaceutical manufacturer founded in 1991 and headquartered in Shunyi, Beijing. It operates as a wholly-owned subsidiary of Shanghai Modern Pharmaceutical Co., Ltd. (国药现代, Shanghai Stock Exchange ticker 600420) under China National Pharmaceutical Group Co., Ltd. (Sinopharm Group), and is ultimately owned by China's State-owned Assets Supervision and Administration Commission (SASAC). The company operates two production bases — Shunyi (Beijing, approximately 100,000 square meters of total land area) and Langfang (Hebei Province, secondary manufacturing base) — and is the national designated manufacturer of narcotic and psychotropic pharmaceutical products in China.

The company's product portfolio spans anesthesia, analgesia, antitussive, cardiovascular, psychiatric, gynecological suppository, and other therapeutic areas, produced under an integrated API-formulation production system. Annual production capacity includes approximately 60 tons of active pharmaceutical ingredients, 50 billion solid oral tablets, 23 million units of small-volume injections and lyophilized powder injections, and 4 million units of oral solutions, plus suppositories and other dosage forms. Core technology platforms include sustained-release microspheres, microreactor technology, chromatographic separation and purification, and impurity reference material preparation, with multiple national invention patents in anesthesia and psychotropic drugs. Recent new product launches (2025-2026) include hydromorphone hydrochloride injection (second domestic manufacturer in China), quetiapine fumarate extended-release tablets (200mg and 300mg), penehyclidine hydrochloride injection, and several new API registrations including ketamine hydrochloride and nalbuphine hydrochloride.

The company's business model is sales-led B2B distribution, organized through four regional sales divisions covering North, East, West, and South China, plus dedicated product-line divisions for anesthesia, analgesics, and commercial management. Revenue is generated through direct sales to domestic healthcare institutions (hospitals, clinics) and retail pharmacy terminals, as well as API/intermediate supply to downstream pharmaceutical manufacturers, with pricing negotiated through government tendering, reimbursement lists, and institutional purchasing agreements. A separate revenue stream arises from registration certificates and consistent-evaluation approvals granted by China's National Medical Products Administration (NMPA), which expand the company's marketable product portfolio.

Name

Sinopharm

Legal name

国药集团工业有限公司

Website

https://cnpicl.com

Company type

Public

Founded year

1991

Operating status

Operating

Headcount range

1–10 employees

Short description

Sinopharm Group Industrial Co., Ltd. is a Chinese state-designated pharmaceutical manufacturer producing narcotic, psychotropic, anesthetic, and analgesic APIs and formulations, operating dual Beijing-Hebei production bases to supply hospitals, retail pharmacies, and drug manufacturers across China.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Medicinal and Botanical Manufacturing (325411), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Controlled Substances / DEA-Scheduled API Manufacturing (HLAGAHAD)

akta.pro secondary industries

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH), Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO)

Keywords

• Pharmaceutical manufacturing
• Narcotic drug production
• Active pharmaceutical ingredients
• Anesthesia and analgesia
• Controlled substance manufacturing

Headquarters

HQ city

Shunyi

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Manufacturing and Sales: Manufactures and sells pharmaceutical products including active pharmaceutical ingredients (APIs), solid oral formulations (50 billion tablets annually), small-volume injections and lyophilized powder injections (23 million units annually), oral solutions (4 million units annually), suppositories, and other dosage forms. Products span anesthesia, analgesia, antitussive, cardiovascular, psychiatric, and other therapeutic areas. Revenue is generated through direct sales to healthcare institutions and retail pharmacy distribution networks across China.
2. New Drug Product Registrations: Generates revenue through registration certificates for new drug products and API approvals from China's National Medical Products Administration (NMPA), including consistent evaluation certifications for generic drugs, expanding the company's product portfolio and market competitiveness.

Go-to-market motion1 record

Distribution channels7 records

Marketing channels3 records

Core offering

Sinopharm Group Industrial Co., Ltd. manufactures and sells active pharmaceutical ingredients (APIs) and finished pharmaceutical products including narcotic and psychotropic drugs, anesthesia agents, analgesics, antitussives, cardiovascular medications, and gynecological suppositories across multiple dosage forms (solid oral tablets, injections, oral solutions, suppositories). The company holds national designated manufacturer status for narcotic drugs in China and supplies healthcare institutions and retail pharmacy networks through regional sales divisions covering North, East, West, and South China. Production is supported by four proprietary technology platforms including sustained-release microspheres, microreactors, chromatographic purification, and impurity reference material preparation.

Product overview

Sinopharm Group Industrial Pharmaceutical Co., Ltd. (国药集团工业有限公司) is a state-designated narcotic drug manufacturing enterprise and wholly-owned subsidiary of Shanghai Sine Pharmaceutical Co., Ltd. (stock code: 600420) under China National Pharmaceutical Group (Sinopharm). The company operates two production bases in Shunyi and Langfang with approximately 100,000 square meters. Annual production capacity includes nearly 60 tons of APIs, 5 billion tablets of solid oral formulations, 23 million units of small-volume injections and freeze-dried powder injections, 4 million units of oral solutions, plus various other dosage forms including suppositories and ironing agents. The company's product portfolio centers on 'one narcotics, three analgesics, one戒 (addiction treatment)' principle, establishing an integrated production system combining narcotic APIs with preparations and full coverage of various dosage forms. The company focuses on anesthesia, analgesia, cough suppression, gynecological suppositories, and cardiovascular therapeutic areas. The company operates with raw material medicine and narcotic preparations supporting each other, with comprehensive dosage form coverage.

Differentiator

Problem solved

Functional benefit

Products and services

• Cardiovascular and Cerebrovascular Medications (心脑血管类药品) Cardiovascular and cerebrovascular medications including indapamide tablets, nifedipine extended-release tablets (Type I and II), simvastatin tablets, perindopril indapamide tablets, and aniracetam dispersible tablets, supplied to hospitals and clinical settings for cardiovascular treatment.
• Analgesic Medications (镇痛药品类) Pain relief medications including paracetamol codeine tablets (Type I and II), lofentanyl tablets, and hydrocodone paracetamol tablets (exclusive product) for clinical pain management.
• Antitussive Medications (止咳药品类) Cough suppressant medications including compound licorice tablets for clinical cough suppression treatment.
• Narcotic Medications (麻醉药品类) Narcotic medications including remifentanil hydrochloride for injection, sufentanil citrate injection, and midazolam injection, supplied as anesthesia agents for surgical and clinical use.
• Other Medications (其他药品类) Other pharmaceutical products including fumarate quetiapine extended-release tablets, fenghan ironing agent, and omeprazole enteric-coated tablets for psychiatric and gastrointestinal therapeutic areas.
• Active Pharmaceutical Ingredients / APIs (原料药) Active pharmaceutical ingredients including nalbuphine hydrochloride, ketamine hydrochloride, and other controlled substance APIs for supply to downstream pharmaceutical manufacturers and internal formulation use.
• Suppository Products (栓剂) Suppository products including metronidazole suppositories, clotrimazole suppositories, acetaminophen suppositories, indomethacin suppositories, and terconazole vaginal suppositories (exclusive) for gynecological and pain management applications.

Quantifiable outcome

• Annual production capacity of ~60 tons of active pharmaceutical ingredients and 50 billion solid oral tablets
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered minor and core.

• Sinopharm (ongoing discussions)minorStrategic or Co-development Partner · 12 May 2026OSR Holdings mentioned ongoing discussions with Sinopharm as part of its strategic developments, alongside a potential $815 million milestone agreement with BCM Europe AG for its oncology drug candidate VXM01. Sinopharm is referenced as a Chinese state-owned pharmaceutical group in the context of potential market entry discussions.
• Sinopharm Group Beijing Huahong (中国医药集团有限公司北京华鸿)coreStrategic or Co-development Partner · 19 March 2026Woori IO Co., Ltd., a South Korea-based subsidiary of OSR Holdings (NASDAQ:OSRH), signed a mutual non-disclosure agreement with Sinopharm Group Beijing Huahong to evaluate potential regulatory, clinical, and commercial pathways for its non-invasive near-infrared glucose monitoring technology in China. The NDA establishes a formal framework for exchanging confidential information for evaluating pathways into China's diabetes market projected to exceed $12 billion by 2032. Sinopharm Group Beijing Huahong is a state-owned Chinese pharmaceutical company engaged in the diabetes care sector.
• 国药乐仁堂唐山有限公司 (Sinopharm Lerentang Tangshan Co., Ltd.)coreStrategic or Co-development Partner · 8 May 2025Sinopharm Group Industrial Co., Ltd.'s Fifth Party Branch conducted a joint party-building activity with the Second Party Branch of Sinopharm Lerentang Tangshan Co., Ltd., focusing on '党建引领促合作、交流互鉴共发展' (Party building leads cooperation, exchange and mutual learning for development). The collaboration aims to deepen party building integration with business operations, share party building experiences, and explore '党建+产业链' cooperation models for market resource integration, supply chain coordination, and regional market collaboration. Joint visits to the Communist Party History Exhibition Hall were conducted.

Scale indicators5 records

Recent moves12 records

Expansion highlights5 records

Broad incumbents

• CSPC Pharmaceutical Group: Large listed Chinese pharmaceutical group with diversified portfolio including CNS, cardiovascular, and anti-infective products; broadly comparable scale, channel access, and R&D capability profile, though more diversified into innovative biologics and oncology than Sinopharm Industrial.
• Shanghai Pharmaceuticals Holding: Central SOE-controlled pharmaceutical group under similar SASAC oversight as Sinopharm Industrial; broadly comparable state-owned pharma operator with overlapping distribution channels and cardiovascular, anti-infective, and API businesses.
• Hengrui Medicine: China's largest listed innovative pharmaceutical company with a broad portfolio across oncology, anesthesia, analgesics, and contrast media; relevant comparable for the anesthesia/analgesic overlap and as the benchmark for Chinese specialty pharma R&D intensity and pipeline.
• Yangtze River Pharmaceutical Group: One of China's largest private pharmaceutical manufacturers with broad generic and innovative product coverage including cardiovascular and analgesic categories overlapping Sinopharm Industrial's portfolio; relevant comparable for scale and generic competition in shared therapeutic areas.
• Joincare Pharmaceutical Group: Mid-large Chinese pharmaceutical manufacturer with respiratory, cardiovascular, and specialty therapeutic areas including some controlled-substance products; relevant comparable for portfolio scale and direct competition in cardiovascular and analgesic categories.
• China Resources Pharmaceutical Group: State-owned pharmaceutical conglomerate under China Resources with generics, APIs, and finished dosage forms across multiple therapeutic areas; comparable as a parallel state-owned platform with similar distribution advantages and regulatory relationships.

Regional players

• Tianjin Tianyao Pharmaceuticals: State-owned Chinese pharmaceutical manufacturer focused on APIs, steroids, and selected finished formulations; directly comparable as a fellow Chinese state-owned API and finished dose manufacturer competing in similar institutional channels.

Direct peers

• Nhwa Pharmaceutical: Specialized Chinese CNS-focused pharmaceutical manufacturer producing psychiatric drugs, anesthetics, and related dosage forms; directly comparable in the psychotropic and controlled-substance product overlap with Sinopharm Industrial's psychiatric medication pipeline.
• Humanwell Healthcare Group: Major Chinese pharmaceutical manufacturer with a strong portfolio in narcotic APIs (codeine, morphine derivatives) and finished dosage forms; the most directly comparable controlled-substance manufacturer and the closest head-to-head competitor in Sinopharm Industrial's core therapeutic areas of anesthesia and analgesia.

Others

• Apeloa Pharmaceutical: Chinese API and intermediate manufacturer serving global generic companies with vertically integrated production; relevant as a comparable Chinese API player whose capabilities overlap with Sinopharm Industrial's API manufacturing business for both internal use and third-party sale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sinopharm